Europe Autoinjectors Market

Market Overview

The Europe autoinjectors market size witnessed significant growth and is expected to grow at a CAGR of around 17.4% during the forecast period (2023-2030).

Highlights

• Anaphylaxis dominates the market by therapy.
• Disposable dominates the market by type.
• Homecare dominates the market by end-user.

Autoinjectors are syringes with pre-filled syringes that have spring-loaded needles and contain dosages of medication. When injected into the body in a sliding motion, the gadget activates and delivers a preset medication dosage. Autoinjectors are used for migraine sufferers to relieve their pain quickly, self-administrate epinephrine (to prevent anaphylaxis), and medical and emergency treatments. Autoinjectors have several benefits, including decreasing the condition of needle-related anxiety, a lower risk of needle-stuck occurrences, maintaining consistent dose quality, and assistance with greater effectiveness.

Market Dynamics

Europe Autoinjectors Market Drivers

Increasing Incidences of Anaphylactic Shock

EpiPens are essential for treating anaphylactic shock in Europe. They allow severe allergy sufferers to self-administer epinephrine in emergencies. Epinephrine can relieve symptoms such as trouble breathing, throat swelling, and low blood pressure, saving lives. Due to escalating anaphylactic shock rates, European autoinjector demand has surged. Pharmaceutical companies have created portable, easy-to-use autoinjectors to meet this requirement. These devices allow anaphylactic patients to receive life-saving therapy anywhere.

Europe Autoinjectors Market Restraints

Increasing Preference for Alternative Drug Delivery Modes

Chronic obstructive pulmonary disease (COPD), common in Europe, is a good example of how inhalation devices and other ways to give drugs have become very popular. COPD is a long-term lung disease that must be treated regularly with medicine. Inhalation devices, such as metered-dose inhalers and dry powder inhalers, deliver drugs straight to the lungs. This makes sure that the therapy works as well as possible. This has led COPD patients to prefer inhalation devices, which could mean there is less need for autoinjectors in this treatment area.

Europe Autoinjectors Market Opportunities

Streamline Regulatory Guidelines

In Europe, the growth of the autoinjector business has been helped by simplifying rules and regulations. The European Union made the Medical Devices Regulation (MDR), which is meant to make medical devices safer for patients and speed up the approval process. By making rules more consistent and easier to understand, the MDR has made it easier for autoinjector makers to get their goods on the market.

Regional Analysis

The Europe autoinjectors market is analyzed by country in the U.K., Germany, France, Italy, Spain, and the Rest of Europe. The rest of Europe dominated the market and is expected to grow at a CAGR of 18.0% during the forecast period.

Due to an aging population with allergies, asthma, arthritis, and chronic diseases, Europe will be the second-largest autoinjectors market. Europeans frequently respond to peanuts, tree nuts, and fish. European food allergy prevalence is unclear. However, 3%–4% of European children and adults have dietary allergies. According to the European Academy of Allergy and Clinical Immunology, 17 million Europeans have food allergies, and hospital referrals for severe responses in children have increased sevenfold over the past decade. Europe PMC research estimates a 3% lifetime prevalence of anaphylaxis. According to the World Allergy Organization, Hungary had the highest anaphylaxis rate in 2017, with 222 out of 10.2 million people with food allergies. Rheumatoid arthritis affects 400,000 Brits. Anaphylaxis is treated with an EpiPen autoinjector to prevent complications and worsening. 

According to the U.K. Asthma Organization, 5.4 million individuals receive asthma therapy, and over 200,000 have severe asthma. Migraines cause 25 million U.K. pupils to miss school or job. Single-use Alsuma autoinjectors are less uncomfortable and better for treating acute migraines.

Due to Emerade autoinjector manufacturing challenges, Europe is experiencing epinephrine autoinjector shortages. Thus, market leaders can concentrate on regional expansion. Adrenaline autoinjectors often fail due to needle blockage. This necessitates patient and caregiver training before device use. Key players can urge autoinjector users to register for the Expiry Alert Service.

Many industry participants have invested in targeted delivery systems, helping the regional market flourish. Targeted delivery allows medications to be delivered to a desired place and avoid harmful regions. Targeted technologies localize pharmaceuticals, improving absorption, circulation of medication levels, and side effects due to greater bioavailability.

Due to increased anaphylaxis rates and AAI prescriptions, the U.K. autoinjectors market will expand quickest. Since 2012, U.K. anaphylaxis rates have increased substantially, according to NCBI. AAI prescriptions are also rising. Thus, the U.K. autoinjectors business is expected to boom.

Segmental Analysis

The Europe autoinjectors market is segmented based on therapy, type, end-user, and country.

The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, Cardiovascular-diseases, and others.

The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 16.3% during the forecast period.

The market is further segmented by type into Disposable, Reusable.

Disposable dominated the market and is expected to register a CAGR of 16.8% over the forecast period.

The market is further segmented by end-user into Hospitals and clinics, home care, and others.

The home care segment dominates the market and is expected to grow at a CAGR of 18.0% during the forecast period.

Recent Developments

• May 2023- B.D. (Becton, Dickinson, and Company), a leading global medical technology company launched a new cell sorting instrument with two breakthrough technologies that allow researchers to discover more cell information than was previously possible in flow cytometry experiments.
• April 2023- Nutriband Inc. and Kindeva Drug Delivery ("Kindeva") selected the target AVERSATM formulation for commercial scale manufacturing process development for the Company's patented lead product, AVERSATM Fentanyl, an abuse-deterrent fentanyl transdermal system.